Special Issue

Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine

Message from the Guest Editor

This is the 4th Special Issue in *Pharmaceuticals* within the last five years dealing with aspects of Radiopharmaceutical Sciences. It demonstrates a significant interest and increasing relevance to ameliorate Nuclear Medicine imaging with PET or SPECT, and also radiotherapeutical procedures. Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. In addition to the classical PET isotopes (18F, 11C, 13N, 15O) further nuclides are available (e.g., 68Ga, 64Cu, 89Zr, 44Sc). There are also new labeling techniques under development to aim for new highly specific tracers (radiopharmaceuticals) to investigate the targets. Large variety of accessible animal and cell models for the preclinical evaluation of targets, mechanisms and tracers have to be highlighted. You are cordially invited to contribute original research, as well as review articles, to this Special Issue. Areas of interest include but are not limited to:

- New targets for imaging
- Tracer developments towards translation
- Multi-modal imaging
- Studies of tumor pathways
- Imaging for therapy monitoring

Guest Editor

Prof. Dr. Gerald Reischl

- 1. Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany
- Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany

Deadline for manuscript submissions

closed (14 January 2019)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/15023

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

